

10

Anaesthesia

ABR Aarvold, J Wiggins, I Sebbag, A Kintu, V Mung'ayi, J Douglas

SYNOPSIS

This chapter is not designed to be an anaesthetic text but focuses on anaesthetic issues specifically related to parturients with hypertensive disorders of pregnancy. Early consultation and involvement of anaesthesia will result in the best possible outcome for women with a hypertensive disorder of pregnancy and their babies. Provision of effective analgesia for labour will not only decrease pain, but also attenuate its effects on blood pressure and cardiac output. In addition, epidural analgesia benefits the fetus by decreasing maternal respiratory alkalosis, compensatory metabolic acidosis, and release of catecholamines. An effective labour epidural can be used should a Caesarean delivery be required, avoiding the need for general anaesthesia. Both neuraxial (epidural, spinal, continuous spinal and combined spinal epidural) and general anaesthesia are appropriate for Caesarean delivery. The choice of technique will depend on the overall condition of the parturient, the urgency of the situation and whether there are contraindications to any particular technique. Challenges associated with anaesthesia include maintaining haemodynamic stability during laryngoscopy and intubation with general anaesthesia, or after sympathetic block secondary to neuraxial anaesthesia. Although neuraxial anaesthesia is preferred to general anaesthesia, owing to potential problems with the airway in the woman with pre-eclampsia, neuraxial anaesthesia may not be possible in the presence of a low platelet count or other coagulation abnormality. The interaction of non-depolarising muscle relaxants (as part of general anaesthesia) and magnesium sulphate will limit their use in the woman with pre-eclampsia. Adequate analgesia and ongoing monitoring are important components of overall postpartum management.

INTRODUCTION

A recurring lesson following investigation of maternal mortality secondary to complications of pre-eclampsia is the importance of teamwork and, in particular, the early involvement of anaesthesia. When possible, the anaesthetic team should be notified when a woman with pre-eclampsia is admitted to hospital. This notification allows for anaesthetic assessment, as well as clinical

optimisation and care planning, all well in advance of anaesthetic intervention. Early anaesthetic consultation is associated with a reduction in both fetal and maternal morbidity¹.

Basic equipment and medications must be available in every labour and delivery area, and operating room in order to monitor maternal and fetal well-being, and resuscitate both should complications arise (Table 10.1). Essential

Table 10.1 Essential equipment for maternal resuscitation

Ventilation	Oxygen source Bag/mask Oral, nasopharyngeal airways
Intubation	Laryngoscope and different blades Different sizes of endotracheal tubes Gum elastic bougie McGill forceps Supraglottic airway device for rescue if failed intubation (e.g., laryngeal mask airway)
Intravenous access	Intravenous catheters (different gauges) Intravenous fluids (e.g., normal saline) Intravenous tubing
Emergency medications	Vasopressors (e.g., phenylephrine or ephedrine) Atropine Epinephrine MgSO ₄ Cardiac medications such as amiodarone Naloxone (for neonatal and maternal resuscitation)
Other	Some means of providing left uterine displacement (e.g., wedge, blankets) Suction Defibrillator Equipment to perform perimortem Caesarean delivery

equipment includes oxygen, suction and a means of monitoring maternal blood pressure and heart rate. Ideally, one also would be able to monitor oxygen saturation and end-tidal carbon dioxide. Equipment for maternal resuscitation should always be immediately available (Table 10.1)². A means of monitoring the fetus and equipment for newborn resuscitation also are required. While all of these resources are considered essential in well-resourced settings, they may not be available in less well-resourced areas. Some of the agents, techniques and equipment discussed in this chapter may not be available, but the basic principles of working as a team and using available resources to ensure the best possible outcome still apply.

The perspective taken in this chapter is that the anaesthetist should participate in a team-based multidisciplinary approach, that includes midwifery, obstetrics, nursing, neonatology and other medical specialties (e.g., haematology) or intensive care, as appropriate.

This chapter aims to highlight the potential issues faced by the anaesthetist when managing a patient with a hypertensive disorder of pregnancy, although the focus of this best anaesthetic practice is on pre-eclampsia. Throughout the chapter, analgesia refers to pain relief which may be provided through pharmacological means (e.g., opioids or gases, such as nitrous oxide) or through a central nerve (neuraxial) block (e.g., epidural) (Figure 10.1) whereby local anaesthetic is deposited close to the spinal cord and nerves to block the sensation of pain. Anaesthesia allows surgery to be performed and may be provided by a neuraxial block (e.g., epidural, spinal that can be continuous or ‘single shot’, or combined spinal epidural) which uses a stronger local anaesthetic than that used for analgesia. Neuraxial anaesthesia provides a denser sensory block in addition to muscle relaxation. Another way of providing anaesthesia is the use of a general anaesthetic that obtunds sensation to the whole body and the brain, resulting in unconsciousness, amnesia, analgesia, muscle relaxation and the inhibition of reflex activity. (For further information on overall anaesthetic concerns, the reader is referred to a basic text on anaesthesia, e.g., *Miller’s Anaesthesia*³.)

INITIAL ASSESSMENT

The aim of the initial assessment is to plan in advance all aspects of both routine and emergency care, anticipate possible problems and the potential for anaesthetic intervention, and discuss any issues identified with the maternity care providers, the woman and her family. The risks and benefits associated with each anaesthetic technique can be explained, with the aim of expediting the process of informed consent should the need arise for an emergency procedure.

Anaesthetic planning should cover all aspects of prenatal maternal optimisation, including provision of analgesia for labour (as applicable), the appropriate choice of anaesthesia for assisted delivery or Caesarean delivery, and a plan for general postpartum care and pain management. Quotes from pre-eclampsia survivors illustrate just how much a multidisciplinary team is needed:

“My blood pressure was 256/120 [mmHg] and doctors couldn’t get it lowered. The doctors decided to put me into a medically induced coma to help stop the swelling of my brain and to try and lower my blood pressure. They




Figure 10.1 Schematic of spinal neuroanatomy, illustrating sites of needle insertion for neuraxial anaesthesia. (Image by DA de Silva © GLOWM)

didn't successfully wake me until Friday morning when I was in labor and it was time to push. They had tried several times to wake me up but . . . I would thrash and struggle and try to pull the intubation tubes from my throat. The first thing I heard when I woke was that I was in the hospital and my baby had died. I was so sedated and drugged all I could say was, 'that's sad' . . . Looking back I realize I had no idea what was actually happening".

Shelly S., HELLP syndrome survivor

A full anaesthetic history and physical examination should be completed, paying particular attention to the maternal airway in case emergency intubation is required, concurrent disease (which is common in this population, Table 10.2), drug history (including potential drug interactions) and end-organ involvement from pre-eclampsia (or another hypertensive disorder of pregnancy).

Women with a hypertensive disorder of pregnancy often have medical comorbidities for which they are receiving therapy, and women with pre-eclampsia have a multisystem disorder by

Table 10.2 Common comorbidities associated with the hypertensive disorders of pregnancy

Comorbidity	Anaesthetic implications
Diabetes mellitus	Regular blood glucose monitoring and BP <140/90 mmHg
Chronic hypertension	Consider the possibility of end-organ damage (e.g., renal disease, left ventricular hypertrophy, or coronary artery disease)
Renal disease	Consider the medication(s) given and their doses Avoid non-steroidal anti-inflammatory drugs Seek specialist advice as required (such as for dialysis)
Obesity	Difficulty with non-invasive monitoring (e.g., correct BP cuff size for accurate measurement, challenging venous access) May require invasive monitoring Increased failure/complications associated with neuraxial techniques Increased incidence of airway problems Need for thromboprophylaxis
Anti-phospholipid antibody syndrome	Patient likely to have been on prophylactic heparin therapy throughout pregnancy
Connective tissue disorders	Wide variety of effects that may require specialist advice

BP, blood pressure

definition (Table 10.3)^{4,5}. Baseline haemoglobin, platelet count, tests of coagulation, renal function and liver enzymes should all be performed whether or not neuraxial analgesia/anaesthesia is considered. The initial results will guide the frequency of further investigations. Also, women with hypertensive disorders of pregnancy (including pre-eclampsia) are often treated with medications that may have implications for anaesthetic management, such as MgSO₄ for eclampsia prophylaxis or nifedipine for hypertension (Table 10.4)^{6,7}.

ONGOING MONITORING

A basic standard of monitoring should be maintained throughout a woman's hospital stay. At minimum, blood pressure, heart rate, oxygen saturation and level of consciousness should be monitored

Table 10.3 Impact of the systemic effects of pre-eclampsia on anaesthesia

<i>System Effect</i>	<i>Anaesthetic implications</i>	<i>Planning considerations</i>
<i>Vascular (BP)</i>		
Hypertension	Potential for extreme hypertension during labour, in response to intubation, or during emergence from general anaesthesia	Regular BP monitoring, invasive monitoring may be required Maintain sBP <160 mmHg
Hypotension	Exaggerated hypotension secondary to neuraxial or general anaesthesia given high sympathetic tone Increased sensitivity to vasoactive drugs	Lateral uterine displacement to avoid aorto-caval compression Cautious boluses of ephedrine or phenylephrine to maintain sBP within 10% of patient's baseline
Generalised oedema	Anticipate that generalised oedema may make venous access challenging	May need central line
<i>Airway</i>		
Laryngeal oedema	Increased risk of difficult intubation or ventilation	Early and continuous assessment Anticipate possible need for intervention, and identify experienced assistance if possible Difficult airway equipment should be available Practice 'can't intubate, can't ventilate' drill ⁴
<i>Cardiac</i>		
Pulmonary oedema	May require CPAP or invasive ventilatory support Potentially difficult ventilation	Careful input/output monitoring and fluid restriction
Cardiac failure with preserved ejection fraction ⁵		Consider non-invasive cardiac monitoring or transthoracic echocardiography Early involvement of intensive care, if indicated
<i>Renal</i>		
Proteinuria	Pulmonary, cerebral, or generalised oedema, even in the absence of nephrotic-range proteinuria	Input/output monitoring
Oliguria		Fluid restriction (to a maximum of 80 mL/h in pre-eclampsia)
Acute kidney injury and electrolyte imbalance	Altered drug clearance Potential arrhythmias	Avoid NSAIDs and other nephrotoxic agents Electrolyte monitoring (including magnesium) and treatment of hyperkalaemia

<i>Hepatic</i>	
Epigastric or RUQ pain	May have rapidly deteriorating function
Elevated liver enzymes	Mainly haematological implications (see below)
Sub-capsular haematoma or rupture	May require surgical intervention
	Early investigation of RUQ pain Frequent re-assessment of function Preparation for laparotomy if required
<i>Haematology</i>	
Haemolysis	Increased risk of neuraxial haematoma with neuraxial techniques
Thrombocytopaenia	Risk of massive haemorrhage
Coagulopathy	May require blood products
	Regular platelet monitoring in respect to performing neuraxial anaesthesia Timely removal of epidural catheters, weighing the risk of removal with the risk of leaving the catheter <i>in situ</i> Avoid non-steroidal anti-inflammatories if there is thrombocytopaenia Monitor fibrinogen levels during haemorrhage Early advice from haematologists Preparation of blood products if required
<i>Neurology</i>	
Eclampsia or PRES	Emergency management of seizures
Altered consciousness	An ongoing deficit and/or evolving clinical picture
Stroke	may affect informed consent or anaesthetic choice
Subarachnoid haemorrhage	(e.g., if there is raised intracranial pressure)
	Seizure prevention preferable (with MgSO ₄) Avoidance or prompt treatment of severe hypertension Any persistent headache/neurological deficit warrants further investigation
<i>Placenta</i>	
Increased risk of abruption causing DIC	Major obstetric haemorrhage
	Immediate Caesarean delivery may be indicated
	See Haematological system Inadequate time for neuraxial technique
BP, blood pressure; CPAP, continuous positive airway pressure; DIC, disseminated intravascular coagulation; sBP, systolic blood pressure; RUQ, right upper quadrant; PRES, posterior reversible encephalopathy syndrome; NSAIDs, non-steroidal anti-inflammatory drugs; MgSO ₄ , magnesium sulphate	

Table 10.4 Pharmacological agents in pre-eclampsia and their impact on anaesthesia

<i>Name of drug</i>	<i>Effect</i>	<i>Anaesthetic considerations</i>
MgSO ₄	Eclampsia prevention and treatment	Awareness of potential toxicity and reversal by calcium gluconate Increased risk of Caesarean delivery Prolonged effect of non-depolarising muscle relaxants No proven increase in the need for neonatal resuscitation ⁶
Nifedipine	Effective, rapid hypertensive control Prolongation of pregnancy Calcium channel antagonist	Rebound tachycardia on induction of anaesthesia Caution when used with magnesium may have increased antihypertensive and negative inotropic effects
Labetalol	Well tolerated, good hypertensive control Specific alpha 1 and non-specific beta adrenoreceptor antagonist	Avoid in asthmatics Fatigue bronchospasm May cause neonatal hypotension and hypoglycaemia
Hydralazine	Increases intracellular cGMP causing decrease in intracellular calcium producing vasodilation	Tachycardia SLE-like syndrome Peripheral neuropathy with longer term use – assess prior to neuraxial block Delayed hypotension with fetal bradycardia
Alpha methyl dopa	Central alpha-2 receptor blocker	May cause bradycardia and haemolytic anaemia
Aspirin	Reduced risk of pre-eclampsia	Low dose (<160mg/d) should not preclude neuraxial technique in the absence of other clotting abnormalities ⁷
Oxytocin	Augmentation of labour Reduced blood loss after delivery	May cause hypotension and should be given slowly and cautiously
Ergometrine	Increases uterine tone after delivery, reduces blood loss	Avoid – may cause severe hypertension
Misoprostol	Increases uterine tone and reduces blood loss after delivery	Hypertension but to a lesser degree than ergometrine
Carboprost	Increases uterine tone after delivery, reduces blood loss	Caution in asthmatics

cGMP, cyclic guanosine monophosphate; MgSO₄, magnesium sulphate; SLE, systemic lupus erythematosus

regularly. It is important to stress that postanaesthetic monitoring and documentation should be equivalent to postoperative monitoring seen in non-obstetric surgical patients⁸.

Blood pressure monitoring should be frequent (and at times continuous) following neuraxial anaesthesia or general anaesthesia, regardless of the severity of hypertension pre-intervention. It may be appropriate to monitor it continuously using an intra-arterial line which is particularly useful when the woman has a very high systolic blood pressure, a very labile blood pressure, or when it cannot be accurately measured (such as in the obese woman for whom a large cuff is required but which fits poorly due to a short upper arm). An arterial line is also useful when frequent blood sampling is required.

Oliguria is a common finding in women with pre-eclampsia, given high sympathetic tone and intravascular volume depletion. There is currently no way of identifying women who will respond adversely to a fluid challenge with pulmonary oedema, so fluid restriction (i.e., administration of no more than 80 mL/h of intravenous fluid) is recommended in pre-eclampsia. (See Chapter 8 for a more detailed discussion of fluid management.)

Early warning systems – integrating routine observations

‘Early warning systems’ are red and yellow colour-coded observation charts onto which a patient’s routine observations are plotted and

deviations from norms of vital signs, symptoms, or signs are flagged for review. These early warning systems have been used widely to trigger early review of 'at risk' medical and surgical patients and, in some circumstances, have been validated as a means of identifying patients who will require critical care⁹.

There is growing enthusiasm for the use of early warning systems to monitor women in pregnancy and postpartum. Although evidence is lacking to fully support the implementation of early warning systems in maternity care, it seems logical that a standardised mechanism to enable early detection and appropriate reporting of the 'at risk' parturient is a prerequisite to reducing maternal morbidity and mortality¹. Table 10.5 presents one published example of a Modified Early Obstetric Warning Systems (MEOWS), with one reading within the 'red zone' or two within the 'yellow zone' triggering urgent review by a consultant¹⁰.

Central venous catheters

Central venous pressure (CVP) correlates poorly with left atrial pressures in severe pre-eclampsia, making absolute values of CVP measurements inaccurate¹¹. However, central venous access may be required for the safe delivery of vasoactive drugs or if generalised oedema makes peripheral access impossible. Under those circumstances, the inserted central venous line may be used to measure *trends* in CVP as a guide to a woman's response to any fluid administered.

Although pulmonary artery catheters are the gold standard for measurement of left and right ventricular filling pressures, there is no evidence from randomised controlled trials to support their use in pre-eclampsia¹². This is unlikely to change owing to the highly invasive nature of the intervention, the significant risk of complications, and the lack of physicians skilled in pulmonary arterial catheter insertion given their infrequent use.

Transthoracic echocardiography

Transthoracic echocardiography (TTE) provides a quick, non-invasive, accurate assessment of fluid status and contractility^{5,13}. Right heart pre-load can be estimated from right and left ventricular end-diastolic volumes, and variations in inferior vena caval diameter with spontaneous respirations. As anaesthetists become more skilled in TTE use,

there is potential to have additional information with which to care for women with hypertensive disorders of pregnancy.

Minimally invasive cardiac output monitoring devices

There is increasing availability of devices to estimate cardiac output at the bedside (e.g., PiCCO, LiDCO, FloTrac/Vigileo systems) and these are used widely in intensive care settings for non-pregnant patients. Although most techniques require that patients be undergoing positive pressure ventilation for accurate results, these devices may provide information about trends that can be used to guide fluid replacement when neuraxial anaesthesia is used. At present, unlike TTE¹⁴, use of non-invasive cardiac output assessment has not been validated for use in maternity care.

Other

The addition of end tidal carbon dioxide monitoring is mandatory during general anaesthesia.

LABOUR ANALGESIA

Maternal pain has physiological effects that may be harmful to the mother and her fetus(es). Pain is associated with increased maternal cardiac output and blood pressure¹⁵⁻¹⁷. Maternal pain is also associated with the following effects that can harm the fetus: (1) respiratory alkalosis (that can shift the maternal haemoglobin-oxygen dissociation curve to the left and reduce oxygenation of umbilical venous blood, as well as cause vasoconstriction and restrict uterine artery blood flow); (2) compensatory metabolic acidosis (that is readily transferred to the fetus); and (3) release of catecholamines that are associated with uncoordinated uterine contractions¹⁸.

Labour analgesia may benefit the hypertensive parturient by attenuating the pain-induced sympathetic response that may contribute to uncontrolled hypertension. In the past, lay individuals and some health care providers assumed that any form of medicinal pain relief was deleterious to the fetus. However, studies focusing on parameters of fetal well-being such as acid-base status, Apgar scores, fetal oxygen saturation and perinatal mortality have demonstrated that effective maternal pain relief (such as with epidural analgesia) is *beneficial* rather than harmful¹⁸.

Table 10.5 Parameters to trigger a response in an early warning system. (Adapted from CEMACH recommended early warning system¹⁰)

Observation	Red trigger		Yellow trigger	
	Low	High	Low	High
Systolic BP (mmHg)	<90	>160	90–100	150–160
Diastolic BP (mmHg)	—	>100	—	90–100
Heart rate (beats per minute)	<40	>120	40–50	100–120 or 40–50
Respiratory rate (breaths per min)	<10	>30	—	21–30
Oxygen saturation (%)	<95	Not applicable	—	Not applicable
Temperature (degrees C)	<35	>38	35–36	—
Pain score	Not applicable	—	Not applicable	2–3
Neurological response	Unresponsive, but responds to pain	Not applicable	Depressed responsiveness, but responds to voice	—
Lochia	Foul smelling	—	Not applicable	—
Proteinuria >2+	>2+	—	Not applicable	—
Amniotic fluid	Green	—	Not applicable	—
Looks unwell	Not applicable	—	Yes	—

BP, blood pressure

Labour analgesia can be provided pharmacologically through three different forms of administration: inhalation, parenteral (by intravenous (IV) or intramuscular (IM) injection), or neuraxial.

Inhalation analgesia

Inhalation analgesia is not used commonly with the exception of the 50:50 mix of nitrous oxide/oxygen (N₂O/O₂). The benefits of N₂O/O₂ include minimal placental transfer, minimal haemodynamic effects, and rapid onset and offset of analgesia. Disadvantages described include nausea and vomiting, and maternal sedation. A meta-analysis summarised the effectiveness of analgesia in 19 randomised controlled trials that compared N₂O/O₂ with other forms of analgesia – placebo, other gases and mixtures, or transcutaneous nerve stimulation (TENS)¹⁹; 17 of these studies were of poor quality and two of fair quality. In the N₂O/O₂ arms, maternal satisfaction with analgesia ranged from 30 to 80%. In a prospective cohort study of good quality, 54% of women who had had N₂O/O₂ were satisfied with

their pain relief compared with 94% of women who received epidural analgesia¹⁹.

Some hospitals have N₂O/O₂ ‘piped-in’ to labour and delivery areas. Those that provide the 50:50 mixture in tanks should ensure that the tanks are stored and handled correctly to ensure that the correct mixture is delivered. When administering the N₂O/O₂ mixture, a demand valve system should be used to ensure that further gas will not be delivered if the woman becomes drowsy. Also, the room in which inhalational analgesia is used should be well ventilated and, ideally, there should be a system for scavenging waste gases. Simple scavenging systems can be made by connecting a corrugated tube that collects the exhaled gases to a vent or exhaust system.

Many centres no longer use N₂O/O₂ given these environmental concerns and the perceived lack of efficacy²⁰.

Parenteral analgesia

Parenteral analgesia is administered commonly in many centres where neuraxial analgesia is not readily available.

Historically, pethidine (meperidine) has been the opioid of choice for labour analgesia, but this practice has changed with the recognition that pethidine has both adverse fetal and neonatal side-effects, including depression of fetal muscular activity, reduction in fetal aortic blood flow, decreased short-term fetal heart rate variability, low Apgar scores, neonatal respiratory depression, reduced neonatal neurobehavioural scores, and weak suckling that could affect breastfeeding¹⁸. Of note, neonatal side-effects may occur up to 72 hours after birth owing to accumulation of pethidine's active metabolite, norpethidine.

The fact remains, however, that all opioids administered parenterally have undesirable maternal and neonatal side-effects. However, IM-administered opioid (pethidine, tramadol, or diamorphine) is not particularly effective compared with placebo²¹, making IV opioid administration the route of choice.

When used during early labour, morphine and fentanyl have minimal neonatal effects. However, owing to their long half-lives, neither drug is recommended for routine use in advanced stages of labour or during delivery, as maternal sedation and neonatal respiratory depression may result²¹.

Remifentanyl is an ultra short-acting opioid that has been investigated for use in IV patient-controlled labour analgesia (PCA). In one meta-analysis of three studies (233 subjects), remifentanyl (compared with pethidine) was more effective (as measured by a reduction of mean visual analogue scale scores for labour pain after 1 hour) and associated with higher patient satisfaction²². In another meta-analysis that reviewed 12 randomised controlled trials (2001–2011) comparing remifentanyl with any other form of labour analgesia²³, 269 women received remifentanyl, 209 pethidine, 10 nitrous oxide and 54 epidural analgesia. Remifentanyl (compared with pethidine) provided superior analgesia, better patient satisfaction, and lower conversion rates to epidural analgesia²³. However, compared with epidural analgesia, remifentanyl was associated with poorer pain control as well as maternal respiratory depression (defined as a maternal oxygen saturation <95%); long-term adverse neonatal effects were not increased²³.

In summary, parenteral opioids should be used when neuraxial analgesia is contraindicated or unavailable. When parenteral opioids are used, careful attention must be paid to maternal

respiration and oxygen saturation, and neonatal resuscitation may be required.

Neuraxial analgesia

Neuraxial analgesia provides the highest quality of pain relief and can be obtained through four different techniques: epidural, combined spinal-epidural, continuous spinal, or 'single-shot' spinal anaesthesia (Figure 10.1). Neuraxial analgesia/anaesthesia is contraindicated when: (1) the patient refuses to consent; (2) there is infection at the proposed site of insertion of the catheter or there is evidence of systemic infection; (3) there is haemodynamic compromise (severe hypotension); or (4) there is evidence of coagulopathy (see Table 10.6, discussed below)²⁴.

Neuraxial anaesthesia/analgesia may be contraindicated in women with pre-eclampsia owing to the presence of coagulopathy. There is debate about the lowest platelet count that is safe for neuraxial anaesthesia, even in normotensive patients²⁵. Many anaesthetists will administer neuraxial anaesthesia when the platelet count is >75,000/mm³ and relatively stable, and there is no clinical evidence of coagulopathy. Not only do platelets need to be sufficient for insertion of a neuraxial catheter, they need to be sufficient at the time of catheter removal. In all cases, the risk–benefit profile of removal versus leaving the epidural *in situ* needs to be addressed. In some cases of pre-eclampsia, the platelet count may take days to normalise; therefore, the risk of epidural infection or trauma from the catheter may outweigh the risk of neuraxial haematoma. Also, as a decreased platelet count may be an indication of disseminated intravascular coagulation (possibly secondary to placental abruption) or other co-existing conditions, one has to consider the relative merits of providing neuraxial anaesthesia with the potential risk of a neuraxial haematoma in each individual patient²⁶.

Epidural analgesia

Maternal pain can be treated effectively with epidural analgesia, without an associated increase in adverse fetal or neonatal effects among normotensive or hypertensive women^{15,27}. In fact, when given to normotensive women, epidural analgesia (compared with either no labour analgesia or opioids, as discussed above) was associated with *better* fetal acid–base status and neonatal Apgar scores¹⁸.

Table 10.6 Coagulation and neuraxial anaesthesia (reproduced from Magee *et al. J Obstet Gynaecol Can* 2014;36: 416–441, with permission)

Treatment with ASA or heparin	Normal platelet count	Low platelet count & normal INR and aPTT	Abnormal INR or aPTT (regardless of platelet count)*
None or Low dose ASA	✓	✓ if platelets >75 × 10 ⁹ /L Unclear if platelets 50–75 × 10 ⁹ /L ✗ if platelets <50 × 10 ⁹ /L	
UFH			
≤10,000 IU/d (SC)	✓ 0–4 h after last dose	Unclear	✗ Contraindicated
>10,000 IU/d (SC)	✓ 4 h after last dose and aPTT normal	Unclear	
Therapeutic dose (IV)	✓ 4 h after last dose and aPTT normal	Unclear	
LMWH			
Prophylactic dose†	✓ 10–12 h after last dose	Unclear	✗
Therapeutic dose‡	✓ 24 h after last dose	Unclear	
Low dose ASA + prophylactic UFH or LMWH**	Unclear††	Unclear	

ASA, aspirin; aPTT, activated partial thromboplastin time; INR, international normalised ratio; LMWH, low molecular weight heparin; SC, subcutaneous; UFH, unfractionated heparin

These recommendations are based on the absence of a rapidly falling platelet count or KNOWN platelet dysfunction (e.g., von Willebrand’s disease)

* Other than a lupus anticoagulant

† Prophylactic dosing is defined as ≤10,000 IU/d

‡ Therapeutic dosing (SC) is defined as >10,000 IU/d

** Prophylactic doses of unfractionated heparin are defined as ≤10,000 IU/d

†† Unless ASA is stopped 7 days or more before delivery

Among hypertensive pregnant women, epidural analgesia attenuates pain-induced elevations in blood pressure and cardiac output¹⁶, as well as providing an option for neuraxial anaesthesia should urgent/emergent Caesarean delivery be necessary for maternal or fetal reasons. An extension of this effect is the potential for hypotension among women with pre-eclampsia who have systemic vasoconstriction and intravascular volume depletion. Although most studies have demonstrated no hypotension among women with pre-eclampsia compared with normotensive women^{27–29}, a recent retrospective controlled cohort study (200 women, 100 with severe pre-eclampsia) did demonstrate more frequent hypotension, late decelerations and vasopressor administration following epidural analgesia compared with normotensive controls³⁰. Although this study did not use hypertensive controls

provided with alternative analgesia, or ideally, randomise women, it highlights the theoretical risk of neuraxial-related hypotension among women with ‘severe’ pre-eclampsia.

It is of particular note that even among women with severe pre-eclampsia, epidural analgesia/ anaesthesia does not increase the risk of Caesarean delivery³¹.

Medications administered through the epidural catheter consist of a combination of a low-dose local anaesthetic (e.g., bupivacaine 0.08%) and an opioid (e.g., fentanyl 2 µg/mL) that provides effective labour analgesia with minimal haemodynamic effect.

Combined spinal-epidural analgesia

Combined spinal-epidural analgesia (CSE) combines the advantages of spinal analgesia (i.e., rapid onset of

pain relief and good analgesia from the insertion of medications into the subarachnoid space) with those of epidural analgesia so that one can provide ongoing continuous pain relief³². CSE analgesia is an acceptable technique for labour analgesia and anaesthesia, but there is some evidence that the use of intrathecal opioids may lead to transient fetal bradycardia (odds ratio 1.8, 95% confidence interval 1.0–3.1)^{33,34}. This fetal bradycardia does not lead to the need for emergency Caesarean delivery (6.0% versus 7.8% for any non-intrathecal opioid technique)³⁴. The proposed mechanism is that the rapid onset of analgesia causes a rapid decrease in beta-adrenergic agonists leading to a predominance of alpha activity. As a result, there is increased uterine contractility and reduced uteroplacental perfusion, with subsequent fetal bradycardia³⁴.

Continuous spinal analgesia

Continuous spinal analgesia (CSA) is more effective than epidural analgesia, as the medications for analgesia (opioid and local anaesthetic) are injected directly into the subarachnoid (intrathecal) space around the spinal cord and cauda equina. This technique is performed by inserting a needle directly into the subarachnoid space and then threading a catheter through that needle. Visual confirmation of cerebrospinal fluid in the hub of the needle identifies correct placement of the needle in the subarachnoid space (prior to insertion of the catheter), making it an easier technique to learn and perform in contrast to inserting a needle into the epidural space where loss of resistance is used to identify the space.

CSA is used in some patient populations as an initial labour analgesia technique (e.g., morbid obesity) as there is a defined end-point (i.e. cerebrospinal fluid) when the space is identified. One of the concerns in identifying the epidural space is that one might inadvertently puncture the dura, but obviously that is not a concern when one is deliberately puncturing it. Increasingly, CSA is used as a rescue technique after accidental dural puncture has occurred inadvertently during attempted epidural insertion; attempting again to identify the epidural space may result in multiple attempts and a second dural puncture.

CSA has the same side-effect profile as epidural analgesia, including risk of postdural puncture headache (see below). However, CSA is associated

with a greater risk of neuraxial infection, as the catheter is in the subarachnoid space and cerebrospinal fluid is an excellent culture medium. Similar to the CSE technique, injection of intrathecal opioids may result in transient fetal bradycardia (see above). In addition, there is greater potential for drug error owing to the injection of medication, intended for the epidural space, through the spinal catheter (because the same type of catheter may be used by most anaesthetists for both techniques). As less medication is required in the subarachnoid space (1–2 mL) than in the epidural space (10–20 mL), inadvertent injection of medication intended for the epidural space into the subarachnoid space can result in a high anaesthetic block and cardiovascular and respiratory impairment. This mandates that an intrathecal catheter for CSA be well labelled and that information is communicated to all care givers that the catheter is intrathecal.

Although controversial, animal studies suggest that use of an indwelling spinal catheter may be associated with a lower incidence of postdural puncture headache. Although two recent meta-analyses did not find a lower incidence of postdural puncture headache in an intrathecal catheter group, compared with a group that had the epidural reinserted, nevertheless, fewer women in the intrathecal catheter group required an epidural blood patch^{35,36}.

'Single-shot' spinal analgesia

Low dose, single-shot spinal analgesia is easy to perform and provides rapid pain relief of a limited duration, depending on the medications used (i.e., 1–3 hours)^{37,38}. This technique is used occasionally in women who are expected to deliver within an hour (because, for example, they are at full cervical dilatation).

Single-shot spinal analgesia is the neuraxial technique that uses the smallest needle (i.e., 24 gauge or smaller, compared with 16–18 gauge needles with other techniques). Some anaesthetists consider the single-shot spinal technique safer than the epidural technique, as the incidence of postdural puncture headache is lower and there is potentially less risk of trauma to neuraxial blood vessels^{39,40}. However, the potential adverse effects are similar to combined spinal-epidural, and include maternal hypotension (that is dose-dependent) and fetal bradycardia³⁴.

CAESAREAN DELIVERY

Cesarean delivery is common, and particularly so among women with pre-eclampsia given uteroplacental dysfunction and the need to deliver some such women at early gestational ages.

Table 10.7 presents the principles of managing an anaesthetic in women with a hypertensive disorder of pregnancy. All neuraxial anaesthetic techniques are appropriate to consider, even in the woman with eclampsia. Among 66 conscious women who had suffered eclampsia but were stable, no major complications occurred in the 37 who underwent epidural anaesthesia and the 27 who underwent general anaesthesia, although the 1-minute Apgar score was higher in the epidural group (related to the temporary depressive effects of the medication used for general anaesthesia)⁴¹. This latter finding is not unexpected as babies born to healthy mothers having general anaesthesia have a lower 1-minute Apgar that recovers by 5 minutes. Factors that influence anaesthetic choice include the need for an emergent Caesarean delivery owing to maternal or fetal concerns, any contraindication to neuraxial anaesthesia, the presence of an existing epidural or spinal catheter in a labouring woman, and maternal choice.

General anaesthesia

The indications for general anaesthesia are similar to those in the general obstetric population. (For further details about mode of delivery, see Chapter 9.) These indications include insufficient time to induce neuraxial anaesthesia (generally owing to fetal concerns or maternal haemodynamic instability) or contraindication(s) to neuraxial anaesthesia, including coagulopathy (Table 10.6), systemic infection, cardiovascular instability, failure to obtain consent, and allergy to any of the anaesthetic agents.

The challenges associated with general anaesthesia are similar to those in normotensive women but the risks may be higher in women with pre-eclampsia. These challenges include the possibility of a difficult airway or failed intubation, the hypertensive response to endotracheal intubation, and haemodynamic instability. If a woman is comatose and has increased intracranial pressure, any further increase in blood pressure during intubation could cause irreversible brain damage. Similarly a drop in blood pressure secondary to sympathetic block with

neuraxial anaesthesia, could compromise cerebral perfusion⁴². The risks associated with pulmonary aspiration secondary to gastric regurgitation have declined due to the almost universal administration of aspiration prophylaxis (with histamine₂ receptor antagonists and prokinetic agents) and 'nothing by mouth' policies once the possibility of Caesarean delivery is raised.

Difficult airway

Although obstetric anaesthetists are concerned about the risks of difficult or failed intubation in any parturient undergoing general anaesthesia, this is a particular concern in women with pre-eclampsia because they may have airway oedema^{43,44}. Airway difficulties are responsible for a substantial part of the increased maternal morbidity and mortality associated with general anaesthesia in women with pre-eclampsia⁴⁵. The Obstetric Anaesthetists' Association and the Difficult Airway Society of the UK have published guidelines for the management of difficult and failed intubation in obstetrics⁴⁶. The algorithms and tables which summarize the management of this situation are available on the websites of the OAA⁴⁷ and the DAS⁴⁸.

Hypertensive response to intubation

In normotensive and hypertensive patients, tracheal intubation may trigger an increase in heart rate and blood pressure⁴⁹. In women with a hypertensive disorder of pregnancy, this hypertensive response may precipitate severe hypertension and an adverse cerebrovascular event (e.g., stroke). As such, it is important to make every effort to attenuate this hypertensive response.

Various pharmacologic approaches to prevention of the hypertensive response to tracheal intubation have been studied in non-obstetric patients, with fewer studied in pregnancy. Randomised controlled trials have compared various agents (with or without control therapy) in patients with pre-eclampsia of various severity. These agents have included opioids (i.e., alfentanil, fentanyl, remifentanyl), antihypertensive agents (i.e., nitroglycerin, labetalol, nifedipine), magnesium and lidocaine. The number of subjects in the individual studies were small and the patient populations were heterogeneous; although most women had received antihypertensive medications preoperatively, others had not and not all were

Table 10.7 Principles of anaesthetic management for Caesarean delivery in women with a hypertensive disorder of pregnancy

Stabilise the woman's BP prior to surgery, if possible. If the BP is severely elevated and uncontrolled, the risks of anaesthesia and surgery will have to be balanced against any potential benefits

Aim for haemodynamic stability perioperatively (avoid hypotension/hypertension)

For spinal anaesthesia, use the smallest available spinal needle, e.g., 24-gauge or smaller, preferably with a pencil point in order to decrease the risk of postdural puncture headache

Consider prophylactic phenylephrine infusion to prevent hypotension during neuraxial anaesthesia (possibly use lower dose than for normotensive parturients)

Avoid a hypertensive response to intubation during general anaesthesia by administering an opioid, remifentanyl (0.0–1.0 µg/kg) or fentanyl (50–150 µg), with or without labetalol (20 mg followed by 10 mg increments until the dBP is decreased to <100 mmHg or mean arterial BP has decreased by 20% from baseline) prior to induction with an adequate dose of thiopental (5–7 mg/kg) or propofol (2–3 mg/kg). Esmolol (1.5 mg/kg) or nitroglycerin (2 µg/kg) combined with propofol (2 mg/kg) have been recommended⁵⁶

Monitor:

- Standard monitors: electrocardiogram, non-invasive BP, oxygen saturation with the addition of temperature and end tidal CO₂ for general anaesthesia
 - Consider intra-arterial BP monitoring if woman requires repeated blood sampling or there is difficulty controlling BP
- Administer oxytocin as an infusion, rather than as a bolus

BP, blood pressure; dBP, diastolic blood pressure; MAP, mean arterial pressure

receiving magnesium. The agents and doses for induction of anaesthesia also varied.

These studies are presented in detail in Appendix 10.1^{50–60}. The bottom-line is that the differences in the protocols of these studies make it difficult to draw firm conclusions as to the best method of attenuating the hypertensive response to intubation, in terms of the individual agent, combination of agents, and/or dose(s). Further study is needed of this important topic. In the meantime, a prudent approach would be to ensure that an optimum dose of an induction agent is used (e.g., thiopental 5–7 mg/kg or propofol 2–3 mg/kg) as well as an opioid. There is little to choose between the opioids, but the advantages of rapid onset and offset of remifentanyl suggest it be used in a dose of 1 µg/kg, where it is available. Alfentanil (10 µg/kg) and fentanyl (50–100 µg) are alternatives to remifentanyl. As most women with pre-eclampsia will be on magnesium, further magnesium should not be given. However, one could consider administering a loading dose of magnesium pre-induction in the circumstance where it has not been given. Sublingual nifedipine 10 mg or labetalol (20 mg loading dose followed by 10 mg increments) to control blood pressure preoperatively are other possible agents. Caution should be exercised, however, as many women with pre-eclampsia may already be on antihypertensive medication; additional antihypertensive medication may lead to hypotension.

Non-depolarising muscle relaxants

Non-depolarising muscle relaxants are used to produce muscle relaxation to facilitate surgery and mechanical ventilation. In women with pre-eclampsia, the combination of a standard dose of a non-depolarising muscle relaxant and MgSO₄ results in prolonged motor block⁶¹, so many consider MgSO₄ to be a relative contraindication to the use of a non-depolarising muscle relaxant. If this combination of therapies cannot be avoided, the dose of the non-depolarising muscle relaxant must be titrated carefully according to monitoring by a peripheral nerve stimulator⁶². Calcium gluconate (or, alternatively, calcium chloride) is the antidote to magnesium and can be used if prolonged neuromuscular block occurs.

Haemodynamic management (i.e., hypotension and hypertension)

Maintenance of a stable blood pressure is key to the successful management of women with a hypertensive disorder of pregnancy. Ideally, the blood pressure will have been stabilised prior to the need for Caesarean delivery. Thereafter, assuming a baseline blood pressure that is <160/110 mmHg (i.e., not severely elevated), one should strive to avoid both falls and rises in blood pressure relative to that baseline.

Maternal blood pressure can be monitored during Caesarean delivery either non-invasively or invasively. If blood pressure monitoring is undertaken non-invasively, the cuff size has to be appropriate for the size of arm. (For more information, see Chapter 1.) Shivering, which often occurs in women having neuraxial anaesthesia (either epidural or spinal), may interfere with non-invasive blood pressure monitoring. Placing the cuff on the wrist (rather than on the upper arm) may decrease interference, although blood pressure measurements taken in this fashion would be used to evaluate trends in blood pressure as wrist measurement is known to overestimate blood pressure⁶³. Invasive blood pressure monitoring achieved by insertion of an arterial line can provide continuous measurement when blood pressure proves difficult to stabilise, and provides the added benefit of allowing repetitive blood sampling.

Some authors suggest that it is more important to focus on cardiac output, rather than blood pressure, during neuraxial anaesthesia for Caesarean delivery in women with severe pre-eclampsia⁶⁴. This can be done using minimally invasive cardiac output monitors^{64,65} or transthoracic echocardiography⁵, as discussed above. The authors who recommend the use of cardiac output suggest that it reflects uterine perfusion better than arterial blood pressure, but this is controversial⁶⁶.

For many years, anaesthetists routinely administered an intravenous bolus (1000–2000 mL) of crystalloid prior to neuraxial block for Caesarean deliveries to avoid hypotension. As most crystalloid intravenous fluid exits the vascular system within 20 minutes of administration, this therapy is ineffective^{67,68}. Most authorities now recommend limiting the amount of intravenous fluid (unless there is ongoing bleeding) in healthy women, administering fluid as a co-load (i.e., administering intravenous fluid after rather than before induction of spinal anaesthesia)^{69–71}. Hypotension is avoided and/or treated through the use of vasopressors (generally phenylephrine). (For further discussion on fluid management, see Chapter 8.)

Vasopressors

In normotensive women, phenylephrine has become the vasopressor of choice to prevent and/or treat hypotension, given its rapid onset and offset that allow for moment-to-moment control of

blood pressure^{66,72}. Ephedrine's popularity as a vasopressor in the setting of neuraxial anaesthesia declined following a study comparing prophylactic infusions of ephedrine and phenylephrine in elective Caesarean deliveries. This study found that umbilical arterial pH was significantly lower in the group receiving the ephedrine (vs. phenylephrine) infusion, even in the presence of good blood pressure control^{66,72}.

In women with pre-eclampsia, there are no studies comparing ephedrine with phenylephrine to prevent or treat hypotension. Although the majority of studies of neuraxial block for Caesarean delivery in women with pre-eclampsia used ephedrine as the vasopressor, the literature is not extensive (as summarised in Appendix 10.2). A prudent approach would be to start with a lower dose of medication (either ephedrine 3–5 mg bolus or phenylephrine 25–50 µg bolus) than one would for normotensive women and titrate the dose to the blood pressure¹³.

Neuraxial anaesthesia

Neuraxial anaesthesia and hypotension

Henke *et al.* reviewed prospective studies that compared haemodynamic changes following spinal anaesthesia, or CSE anaesthesia, with epidural and/or general anaesthesia for Caesarean delivery in severe pre-eclampsia⁶⁸. They reported on three trials that studied the haemodynamic changes after spinal anaesthesia for non-emergency Caesarean delivery, comparing women with severe pre-eclampsia (N = 115) with normotensive women (N = 121). In all three of these studies, the group with severe pre-eclampsia had a lower incidence of hypotension and required less ephedrine to treat hypotension than did the normotensive controls⁶⁸. In two of these studies, many of the women with severe pre-eclampsia delivered at an earlier gestational age (lower fetal weight), raising the possibility that women with severe pre-eclampsia had less hypotension because their fetuses were smaller and caused less aortocaval compression^{73,74}. Therefore, the third study compared normotensive women delivering at an earlier gestational age (fetal weight was similar); once again, the incidence of hypotension requiring treatment was lower in the pre-eclampsia group ($p < 0.03$).

In addition to the three studies identified by Henke *et al.*, a study by Tihtonen *et al.* used

non-invasive whole-body impedance cardiography to assess the impact of spinal anaesthesia for Caesarean delivery on maternal haemodynamics in women with pre-eclampsia (N=10; 6 were severe) with comparative data from a historic cohort of normotensive (N=10) women⁷⁵. The incidence of hypotension differed between the groups (normal=80% vs. pre-eclampsia=30%). Women with pre-eclampsia had a low cardiac index and high systemic vascular resistance index preoperatively and, while cardiac index remained stable after induction of spinal anaesthesia, systemic vascular resistance index decreased. Following delivery, the mean cardiac index increased due to an increase in heart rate (with no associated increase in stroke index). The authors raised the possibility that women with pre-eclampsia were unable to increase stroke index and that this might increase the risk of pulmonary oedema⁷⁵. One observational study looked at cardiac output using minimally invasive monitoring in 15 women with severe pre-eclampsia undergoing Caesarean delivery under spinal anaesthesia⁶⁵; there was a modest afterload reduction with minimal cardiac output change following spinal anaesthesia in women with severe pre-eclampsia. This led them to conclude that spinal anaesthesia is associated with adequate haemodynamic stability⁶⁵.

Spinal anaesthesia versus epidural anaesthesia in women with pre-eclampsia

Two prospective studies compared epidural anaesthesia (N=57) with spinal anaesthesia (N=64) in women with severe pre-eclampsia^{76,77}. The larger of these studies found a higher incidence of hypotension (systolic blood pressure <100 mmHg) in the spinal group compared with the epidural group (51% vs. 23%) but the duration of hypotension was short (median 1 min vs. 0 min). From induction of anaesthesia to delivery of the fetus, there was a significant difference in the lowest systolic blood pressure ($p < 0.001$), diastolic blood pressure ($p < 0.005$) and mean blood pressure ($p < 0.001$) between the epidural and spinal groups. The total dose of ephedrine to treat hypotension, although greater in the spinal group, was nevertheless small (12 mg – spinal; 6 mg – epidural)⁷⁶. The smaller study (total of 21 subjects) found a similar incidence of hypotension and ephedrine dose between the two groups⁷⁷.

In addition to these prospective studies identified by Henke *et al.*, there have been two retrospective studies comparing spinal with epidural anaesthesia^{78,79}. The study by Hood *et al.* looked at women with severe pre-eclampsia who received spinal anaesthesia (N=103) or epidural anaesthesia (N=35) for Caesarean delivery⁷⁸. Similar to the prospective studies, the lowest mean blood pressure and ephedrine use were similar between the groups. In a similar retrospective study, the incidence of hypotension and ephedrine use were similar between spinal (N=70) and epidural (N=51) anaesthesia in women with pre-eclampsia⁷⁹; the only difference in this study was that there were some women in each group who were classified as having mild-moderate pre-eclampsia (41 in the spinal group vs. 18 in the epidural group).

Only one prospective study compared CSE (N=27) with epidural (N=27) and general anaesthesia (N=26)⁸⁰. It is important to note that the dose of hyperbaric bupivacaine administered in the spinal component of the CSE in this study is similar to that used by many anaesthetists for single-shot spinal (11 mg). The authors do not report on whether the CSE group required epidural top-up doses but given the intrathecal dose, one could consider this group as receiving spinal anaesthesia. Blood pressure was lower at the time of skin incision ($p < 0.003$) and treatment with ephedrine boluses was higher in the CSE and epidural groups (compared to the general anaesthesia group) (0 mg general anaesthesia vs. 8 mg epidural vs. 6 mg CSE) ($p < 0.009$). As well, significantly more IV fluid was administered in the neuraxial groups (2387 ± 110 epidural, 2255 ± 102 mL spinal) compared to the general anaesthetic (1537 ± 101 mL) group ($p < 0.001$)⁸⁰.

Spinal anaesthesia (CSE) versus general anaesthesia in women with pre-eclampsia

In Henke *et al.*'s review⁶⁸ there was one study that compared general anaesthesia (N=35) to spinal anaesthesia (N=35) (other than for the Wallace study that used CSE, rather than single shot spinal)⁸¹. The primary outcome in this study was umbilical arterial base deficit; they considered a difference of >8 mEq/L to be clinically significant⁸¹. Of note, this study was done in women undergoing emergent Caesarean delivery for a non-reassuring fetal heart rate. Although there was a higher base

deficit (7.1 vs. 4.7 mEq/L, $p=0.02$) and lower median umbilical artery pH (7.20 vs. 7.23, $p=0.046$) in the spinal group compared to the general anaesthesia group, the authors felt that the clinical significance was uncertain, as there was no difference in requirement for neonatal resuscitation⁸¹. As with other studies, the dose of ephedrine used to treat hypotension was higher in the spinal group (14 vs. 8 mg, $p=0.002$). The dose of ephedrine did not correlate with umbilical artery base deficit.

In conclusion, spinal anaesthesia is considered to be safe in women with severe pre-eclampsia, providing there are no contraindications to its use (such as coagulopathy). More research is needed in this area, particularly with respect to vasopressor use. Although phenylephrine is used by most anaesthetists for prophylaxis and treatment of hypotension in normotensive women receiving neuraxial anaesthesia, only one study used phenylephrine to treat hypotension⁶⁵; the rest used ephedrine. Studies are required comparing phenylephrine with ephedrine in women with severe pre-eclampsia.

Spinal anaesthesia

Spinal (vs. epidural) anaesthesia provides more rapid onset, more profound block, and a lower incidence of patchy/failed anaesthesia⁸². Also, if a blood vessel is inadvertently punctured during spinal anaesthesia, the hole is smaller than that from an epidural needle, potentially decreasing the risk of a neuraxial haematoma.

In the past, spinal anaesthesia was considered to be contraindicated in women with pre-eclampsia owing to the fear of precipitating potentially fatal hypotension. However, several randomised controlled trials of women with pre-eclampsia have shown that the incidence of hypotension following spinal anaesthesia is actually *lower* than among healthy women, and that hypotension is easier to treat^{73,74,83}.

Some anaesthetists now use continuous spinal anaesthesia for Caesarean delivery. With continuous spinal anaesthesia, the local anaesthetic can be titrated to achieve the desired level of anaesthesia. Although spinal microcatheters (27–32 gauge) have been used in the past for continuous spinal anaesthesia, many anaesthetists now use a macrocatheter (20–22 gauge epidural catheter) as it

is easier to insert than the microcatheter. Not only will some anaesthetists insert a standard epidural catheter if an accidental dural puncture occurs during attempted epidural or CSE anaesthesia, but some will electively insert it in a patient when difficulty with insertion is anticipated, such as a morbidly obese parturient. Potentially, continuous spinal anaesthesia using a macrocatheter carries a greater risk of postdural puncture headache and neuraxial haematoma, than when single-shot spinal anaesthesia is done with a smaller needle, although this is controversial.

Epidural anaesthesia

Epidural anaesthesia is not used commonly for Caesarean delivery unless the woman already has an epidural catheter in place for labour analgesia. The larger epidural needle, the slower onset of anaesthesia, the higher incidence of shivering, and the higher incidence of patchy/failed anaesthesia are potential disadvantages of epidural anaesthesia. The major advantage of epidural anaesthesia, compared to single-shot spinal anaesthesia, is the slower onset of sympathetic block, making it easier to titrate vasopressors to avoid/treat hypotension.

Combined spinal-epidural analgesia

CSE combines the advantages and disadvantages of spinal and epidural anaesthesia. Some studies suggest that combined spinal-epidural is advantageous in women with pre-eclampsia as one can use a lower intrathecal dose to initiate anaesthesia and then use the epidural catheter to adjust the height of the block^{84,85}. The effective dose of medication does not appear to be different in women with (as opposed to those without) pre-eclampsia⁸⁶.

Local anaesthetic infiltration

Rarely general anaesthesia and neuraxial anaesthesia may not be available for Caesarean delivery owing to a lack of anaesthetic services or contraindications to both techniques related to the parturient's underlying disease. Under these circumstances, the only option is for the obstetrician to infiltrate the layers of the wound with local anaesthetic^{87,88}. This technique uses a dilute concentration of local anaesthetic (e.g., 0.5% lidocaine) combined with epinephrine (i.e., 1:200,000) to limit absorption

and decrease the risk of local anaesthetic toxicity. As there is less dense anaesthesia, the surgeon has to handle the tissues gently or the patient will complain of pain.

Other considerations

Ergometrine is contraindicated in women with pre-eclampsia.

Oxytocin is usually administered after delivery of the baby to prevent postpartum haemorrhage. However, oxytocin should be administered by infusion and carefully titrated to effect¹³. Oxytocin should not be administered by bolus injection; using continuous minimally invasive haemodynamic monitoring in 18 women with 'severe' pre-eclampsia, 5IU of oxytocin by IV bolus was associated with an increase in heart rate, increase in systemic vascular resistance, and fall in blood pressure⁸⁹. Five of the 18 women had a decrease in cardiac output as they could not increase their stroke volume.

POSTPARTUM ISSUES

It is essential that postpartum, anaesthesia assesses every woman who has received anaesthetic care for potential complications and pain control. In women whose labour and delivery was uncomplicated, little or no analgesia may be required, but those who have had a long, difficult labour or operative delivery may require a more complex plan.

Anaesthetic complications – early and delayed

Depending on the type of anaesthesia given, there is a range of complications that need to be addressed should they arise in the postoperative period.

Early

In the immediate postoperative period, respiratory depression, labile blood pressure, oxygen desaturation and cardiac changes can all occur. The woman should be closely monitored in a recovery unit by someone trained in recovery care until the patient is fully awake (i.e., able to appropriately answer questions and maintain her own airway) and stable from a cardiovascular perspective⁸. The type of monitoring should include, at minimum, measurement of blood pressure non-invasively, heart rate, oxygen saturation and level of consciousness. Also, as most women undergoing

general anaesthesia will have received a neuromuscular blocking agent, it is important to monitor return of neuromuscular function. Several maternal deaths have occurred in the immediate postoperative period secondary to respiratory failure (sometime owing to inadequate reversal of neuromuscular blockade⁹⁰).

While postoperative nausea and vomiting may occur following neuraxial opioids, they are more likely to occur following general anaesthesia and postoperative orders should include provision for administration of anti-emetic medications.

The challenge of balancing the need to induce general anaesthesia rapidly for the sake of the fetus/newborn while anaesthetising the mother, may lead to maternal awareness (i.e., recall of events when the patient was thought to have been anaesthetised)⁹¹. Caesarean delivery is one of the most common surgical procedures that lead to awareness given the lower doses of anaesthetic agents used in an effort to minimise effects on the fetus(es)⁹². Specific questioning of the mother in the postoperative period should be undertaken following any obstetric general anaesthetic in order to detect awareness⁹³. If awareness is detected, a full explanation should be provided and an appropriate referral should be made for psychological assistance as post-traumatic stress disorder may otherwise arise⁹⁴.

Also, if a complication(s) has(have) occurred during the provision of general anaesthesia (such as dental damage or difficult intubation), the woman should be informed about these. Consideration should be given to providing written information about the nature of the complication and how it was managed. Also, the woman should be instructed to give the letter to her anaesthetist prior to any future anaesthetic.

Delayed

Potentially delayed complications of regional anaesthesia vary in their severity and incidence (Table 10.8).

Dural puncture is one of the most common complications. A meta-analysis of obstetric studies in this area found the incidence of accidental dural puncture to be 1.5%, with 50% of these patients going on to develop a postdural puncture headache⁹⁵. The incidence varies greatly from one centre to another, with the number of epidurals inversely related to the number of complications⁹⁶.

Table 10.8 Postoperative complications secondary to regional anaesthesia

<i>Procedure</i>	<i>Complication</i>	<i>Sign</i>
Epidural or spinal	Spinal haematoma	Back pain, neurological signs
	Epidural haematoma	Back pain, neurological signs
	Dural puncture	Severe postural fronto-occipital headache/neck ache, visual disturbances
	Direct nerve damage	History of pain on injection, neurological signs
	Epidural abscess	Back pain, neurological signs, fever
	Meningitis	Fever, headache
Local anaesthetic wound infiltration	Infection	Fever
	Displacement	Pain
	Local anaesthetic toxicity	Neurological and cardiac symptoms (end result cardiac arrest)

Serious complications are rare. For example, spinal haematoma occurs in about 1:168,000 epidurals⁹⁷, and even less frequently following spinal anaesthesia. Nerve damage can occur temporarily in about 1 in 3000 patients, and permanently (i.e., for more than 6 months) in about 1 in 15,000 patients⁹⁸. Meningitis following neuraxial anaesthesia is also a very rare complication, ranging in reported incidence from 1:50,000⁹⁹ to fewer than 1:200,000¹⁰⁰.

Pain

Once the patient is stable and she has been transferred to the ward, the main challenge will be pain management, especially in the absence of any supplemental regional anaesthesia.

Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage. Table 10.9 outlines the physiological effects of pain which include, but are not limited to, an increase in blood pressure.

There is scant literature on postpartum analgesia in women with a hypertensive disorder of pregnancy, so the management approach is based on general principles of postpartum care. Ideally, the plan for pain control will include a means of preventing pain (prophylaxis) and a means of treating breakthrough pain. Regularly administered medication via a variety of routes (multimodal) provides a baseline level of analgesia and is generally ordered for 24–48 hours postpartum. Additional oral or IV analgesics are ordered for breakthrough pain. For women planning an elective Caesarean

Table 10.9 The physiological effects of pain

<i>System</i>	<i>Effect</i>
Cardiovascular	Increased heart rate Increased blood pressure Increased peripheral vascular resistance Increased myocardial oxygen consumption → potential for myocardial ischaemia
Respiratory	Diaphragmatic splinting
Gastrointestinal	Delayed gastric emptying Decreased bowel motility
Psychological	Anxiety Sleeplessness Low morale Postpartum depression
Neurological	Chronic pain (in up to 10% of patients postCaesarean delivery)

delivery, some form of preoperative patient education may be useful in managing patients' expectations and advising on coping strategies (e.g., finding alternative ways of performing tasks that may cause pain and limiting certain activities, such as lifting).

A commonly used approach to pharmacological management is the WHO analgesic ladder, beginning with: (1) non-opioid analgesic, then adding (2) opioid for mild to moderate pain, and then (3) spinal/epidural opioid or patient-controlled analgesia, with or without other techniques, as necessary (e.g., local wound infiltration with anaesthetic) (Figure 10.2)¹⁰¹.




Figure 10.2 WHO analgesic ladder¹⁰¹. (Adapted for use with permission)

Oral/rectal analgesics

The non-opioid oral analgesics, paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) (Step 1, Figure 10.2) give a good base on which to build further medication needs. Both drugs are acceptable for use in breastfeeding mothers. Paracetamol (acetaminophen) is well-tolerated and demonstrates excellent synergy with many other analgesics. NSAIDs are very useful analgesics, but caution should be exercised in women with a hypertensive disorder of pregnancy. NSAIDs (e.g., ibuprofen, diclofenac, ketorolac) have antiplatelet effects (which may be an issue in the face of thrombocytopenia); they may increase blood pressure¹⁰², and they may reduce renal perfusion (and should therefore, not be used in the woman with renal dysfunction from pre-eclampsia).

Oral opioids (e.g., morphine, hydromorphone, oxycodone) are effective in managing moderate pain (Step 2, Figure 10.2). The American Academy of Pediatrics, the European Medicines Agency and the UK's Medicines and Healthcare Products Regulatory Agency all recommend against use of codeine during breastfeeding^{103,104} as a maternal rapid acetylator phenotype may result in excessive levels of active metabolites in breast milk.

Non-opioids and opioids are usually administered orally, but an alternative route of administration is rectal. Of course, opioids can be administered by IV injection.

IV analgesics

When oral/rectal administration is not an option, pain is severe (e.g., postoperatively), or a rapid-onset of analgesia is required, IV analgesics may be used either alone or as a supplement to oral analgesics (Step 3, Figure 10.2). IV analgesics act more quickly because IV administration avoids 'first-pass' hepatic metabolism. IV analgesics are also often more potent than those administered via other routes.

The commonly used IV medications are morphine based. They are administered by the nurse or physician, or via a patient-controlled analgesia (PCA) pump. While IV opioids are an excellent option for urgent analgesia, their use should be limited as there is the potential for tolerance and addiction. In addition to IV opioids, some oral analgesics (e.g., paracetamol, ketorolac, NSAIDs) are available for intravenous use.

Some IV medications, that were not used previously for analgesia, such as ketamine and magnesium, are being investigated for their analgesic properties. When ketamine is used in low doses during general anaesthesia¹⁰⁵, it has a morphine-sparing effect that lasts longer (i.e., up to 24 hours) than one would anticipate based on the half-life of the drug. MgSO₄ also has some analgesic effect¹⁰⁶, an 'added bonus' in women who are administered it for eclampsia prophylaxis or treatment, or fetal neuroprotection; at present, MgSO₄ is not recommended for administration as an analgesic *per se*. (For more information, see Chapter 8.)

Neuraxial analgesia

A neuraxial catheter generally is removed postoperatively unless there are concerns about haemostasis or coagulation. Without a supplemental opioid, analgesia can be anticipated for 1–2 hours after spinal anaesthesia and 1–4 hours after epidural anaesthesia/analgesia, depending on the local anaesthetic used and the dose injected. When an opioid (e.g., morphine or diamorphine) is included in the spinal injectate or when an opioid is injected through the epidural catheter, effective postpartum analgesia may last up to 24 hours; the actual duration is dependent on the dose¹⁰⁷.

The commonly used opioids for this purpose are morphine, fentanyl and diamorphine, although some countries use pethidine (such as Australia). Other medications under investigation for neuraxial analgesia include MgSO₄ for its morphine-sparing action¹⁰⁸ and clonidine for prolonging spinal anaesthesia and improving early analgesia¹⁰⁹.

Another way of providing postoperative analgesia in a patient is to administer a continuous local anaesthetic±opioid mixture through a pre-existing neuraxial catheter (epidural or spinal) by continuous infusion or patient-controlled epidural analgesia. While use of a neuraxial catheter is an effective way of providing postpartum analgesia, it is more complex. The catheter may limit patient mobility and the longer it is in place, the greater the risk of infection. This approach is generally avoided in obstetric cases unless extensive surgery has been required (e.g., laparotomy for complications) and postoperative pain control is a concern (e.g., in patients with contraindications to opioids and NSAIDs). Even in these rare cases, nurses caring for these patients postoperatively must be experienced in the management of neuraxial analgesia.

Other methods

Following general or neuraxial anaesthesia for Caesarean delivery, wound infiltration and abdominal nerve blocks reduce opioid consumption postpartum (20 trials, 1150 women)¹¹⁰. Bupivacaine-soaked sponges have been described to reduce postoperative opioid and diclofenac consumption¹¹¹.

Postoperative wound infusion is a technique whereby a catheter is inserted superficially into the abdominal wound and local anaesthetic is continuously infused. It is a technique with mixed reports of success^{112–114}. A recent study suggests that subfascial placement is superior and that multiholed catheters provide better analgesic outcomes¹¹⁵. The catheter is generally placed intraoperatively just before closure of the fascia and should block superficial nerves around the wound. Inadvertent intravascular injection could result in cardiovascular and central nervous system collapse.

Transversus abdominis plane blocks often are used when neuraxial analgesia is unavailable (e.g., following general anaesthesia). They are often placed under ultrasound guidance into the transversus abdominal plane and are performed bilaterally. This is a single-shot technique and more nerves are blocked than during wound infusion. A correctly placed transversus abdominis plane block should block intercostal nerves (T7–T11), the subcostal nerves (T12) and the iliohypogastric and ilioinguinal nerves (L1). A meta-analysis by Mishriky *et al.* (9 trials, 554 patients) found that bilateral transversus abdominis plane blocks, in the absence of intrathecal morphine, are effective for post-Caesarean analgesia; however, when intrathecal (spinal) morphine has been used, there is no additional benefit of a transversus abdominis plane block. Intrathecal morphine alone provides better analgesia than transversus abdominis plane blocks alone, although this is at the expense of morphine-related side-effects¹¹⁶. A randomised controlled trial comparing transverse abdominal plane blocks with wound infiltration (both combined with paracetamol and NSAIDs) found no difference in cumulative morphine consumption following Caesarean delivery¹¹⁷. The authors recommended wound infiltration over transverse abdominal plane blocks owing to the resources and time required to do transverse abdominal plane blocks, but they acknowledged that further studies are required.

Intrathecal opioid followed by postoperative bilateral ilioinguinal nerve blocks is an approach associated with reduced morphine use postpartum¹¹⁸, although there is no reduction in morphine-related side-effects¹¹⁹.

BEST PRACTICE POINTS

(Please see Appendix 10.3 for the evaluation of the strength of the recommendation and the quality of the evidence on which they are based.)

1. The anaesthetist should be informed when a woman with pre-eclampsia is admitted to the delivery suite.
2. Women with pre-eclampsia should have a platelet count on admission to the delivery suite.
3. Planning for the care of women with pre-eclampsia should include members of the multi-disciplinary team.
4. The anaesthetist should assess the woman with pre-eclampsia from the standpoint of possible anaesthetic care and as her status may change, she should be reassessed.
5. Arterial line insertion may be used for continuous arterial blood pressure monitoring when blood pressure control is difficult or there is severe bleeding. An arterial line also is useful when repetitive blood sampling is required, e.g., in women with HELLP (haemolysis, elevated liver enzymes, low platelet) syndrome.
6. Central venous pressure monitoring is not routinely recommended and, if a central venous catheter is inserted, it should be used to monitor trends and not absolute values.
7. Pulmonary artery catheterisation is not recommended unless there is a specific associated indication and then only in an intensive care setting.
8. Early insertion of an epidural catheter (in the absence of contraindications) is recommended for control of labour pain.
9. In the absence of contraindications, all of the following are acceptable methods of anaesthesia for women undergoing Caesarean section: epidural, spinal, continuous spinal, combined spinal epidural and general anaesthesia.
10. A routine, fixed intravenous fluid bolus should not be administered prior to neuraxial anaesthesia.
11. Neuraxial analgesia and/or anaesthesia are appropriate in women with hypertensive disorders of pregnancy provided there are no associated coagulation concerns (Table 10.5) or specific contraindications as noted earlier in the text.

PRIORITIES FOR UNDER-RESOURCED SETTINGS

While all of the resources discussed in this chapter are considered to be essential for care of women with hypertensive disorders of pregnancy in well-resourced settings, these materials may not be available in less well-resourced areas. However, basic principles apply in all settings – working as a team to provide multidisciplinary care, and using available resources to ensure the best possible outcome for mother and baby(ies). Table 10.10 outlines suggested priorities according to the level of the health care service, with primary health centres designed to provide BEmONC and facilities designed to provide CEmONC.

A key feature of any priority-setting exercise is action and evaluation. As such, routine monitoring and evaluation of obstetric anaesthesia services must be undertaken to help improve the quality of maternity care¹²⁰. A key component of future

priorities is the proper training of non-physician anaesthesia providers, with emphasis on provision of resuscitation and regional anaesthesia techniques, since most of anaesthetics in sub-Saharan Africa are provided by this cadre of people¹²¹; also, these individuals can assist in providing adequate pain management for both Caesarean deliveries and vaginal deliveries, utilising simple and inexpensive methods such as single-shot spinals¹²² (Figure 10.3). The availability of blood products is discussed in Chapter 8, but transfusion protocols for blood loss antenatally or postnatally should be in place in every unit^{123,124}.

WHAT INTERNATIONAL GUIDELINES SAY

In a review of international guidelines, only the Canadian guidelines^{24,125} present a detailed list of recommendations for anaesthetic management. The latest update from the National Institute for

Table 10.10 Priorities for obstetric anaesthesia by level of health care system at which care is delivered

<i>Antepartum and postpartum</i>		
	<i>Initial priority</i>	<i>Ultimate goal</i>
<i>Community</i>		
Primary health care centre for provision of BEmONC	<p>Availability of essential equipment for monitoring, consisting of a means of measuring BP and heart rate</p> <p>Some means of providing left uterine displacement (e.g., wedge, blankets)</p> <p>Availability of essential equipment for maternal resuscitation, consisting of oxygen, suction, and intravenous access (see Table 10.1 for details)</p> <p>Provision of pain relief (inhalational or systemic opioids) for vaginal delivery</p>	<p>Ability of oxygen saturation monitoring</p>
<i>Facility</i>		
Secondary-level (for provision of EmONC)	<p>Assess gestational age accurately</p> <p>Availability of essential equipment for monitoring, consisting of a means of measuring BP and heart rate</p> <p>Ability to monitor maternal well-being with laboratory testing* (blood and urine)</p> <p>Some means of providing left uterine displacement (e.g. wedge, blankets)</p> <p>Ability to monitor fetus with NST</p> <p>Availability of essential equipment for maternal resuscitation, consisting of oxygen, suction, equipment for intubation and ventilation, intravenous access, and emergency medications (see Table 10.1)</p> <p>Defibrillator</p> <p>Equipment to perform peri-mortem Caesarean delivery</p> <p>Provision of adequate pain relief for vaginal delivery and postCaesarean delivery (by inhalational or systemic means)</p>	<p>Ability to monitor oxygen saturation and end-tidal carbon dioxide</p> <p>Ability to monitor fetus with ultrasonographic assessment</p> <p>Provision of anaesthetic management (including neuraxial analgesia such as single-shot spinal) by non-physician provider</p> <p>Transfusion protocol</p>
Tertiary-level (referral) for provision of EmONC	<p>Assess gestational age accurately</p> <p>Availability of essential equipment for monitoring, consisting of a means of measuring BP and heart rate</p> <p>Ability to monitor maternal well-being with laboratory testing* (blood and urine)</p> <p>Some means of providing left uterine displacement (e.g., wedge, blankets)</p> <p>Monitor fetal well-being with NST and ultrasonographic assessment</p>	<p>Ability to monitor oxygen saturation and end-tidal carbon dioxide</p> <p>Provision of anaesthetic management (including neuraxial analgesia) by non-physician provider</p> <p>Transfusion protocol</p>

continued

<i>Antepartum and postpartum</i>	
<i>Initial priority</i>	<i>Ultimate goal</i>
Availability of essential equipment for maternal resuscitation, consisting of oxygen, suction, equipment for intubation and ventilation, intravenous access, and emergency medications (see Table 10.1)	
Defibrillator	
Equipment to perform peri-mortem Caesarean delivery	

BP, blood pressure; NST, non-stress test

* Complete blood count, coagulation, serum creatinine, and liver enzymes, at minimum




Figure 10.3 Performing single-shot spinal anaesthesia in Uganda

Health and Care Excellence (NICE) in the UK includes references to the use of remifentanyl for labour analgesia and to ablate the hypertensive response to intubation¹²⁶. The recommendations from this review of guidelines are presented in Appendix 10.4¹²⁷. In addition, the Australasian guideline presents discussion of anaesthetic issues that are in agreement with the Canadian guideline, in terms of early involvement of the anaesthetist in the care of women with pre-eclampsia on delivery suite, no pre-loading with fluid prior to neuraxial anaesthesia, epidural analgesia as an adjunct to antihypertensive therapy, and low-dose aspirin as compatible with regional analgesia/anaesthesia; also the Australasian guidelines do a particularly good job of highlighting the potential airway problems associated with pre-eclampsia and the importance of attenuating the hypertensive response to endotracheal intubation¹²⁸.

PRIORITIES FOR FUTURE RESEARCH

Priorities for future research include:

- How can we improve maternal monitoring intrapartum, including maternal fluid status?
- Does haemodynamic monitoring during antihypertensive therapy improve maternal and perinatal outcomes?
- What is a safe platelet count for neuraxial block?
- What is the most appropriate vasopressor (and dose) for the prevention and treatment of hypotension following neuraxial block?
- What is the most appropriate strategy to manage postpartum pain?

REFERENCES

1. Wilkinson H. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008. *BJOG* 2011;118(S1):1–203
2. Lipman S, Cohen S, Einav S, Jeejeebhoy F, Mhyre JM, Morrison LJ, et al. The Society for Obstetric Anesthesia and Perinatology consensus statement on the management of cardiac arrest in pregnancy. *Anesth Analg* 2014 May;118(5):1003–1016
3. Miller RD, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Young W. *Miller's Anesthesia*, 8th edn. Philadelphia, PA: Elsevier/Saunders; 2015
4. Apfelbaum JL, Hagberg CA, Caplan RA, Blitt CD, Connis RT, Nickinovich DG, et al. Practice guidelines for management of the difficult airway: an updated report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. *Anesthesiology* 2013 Feb;118(2):251–270

THE FIGO TEXTBOOK OF PREGNANCY HYPERTENSION

5. Dennis AT, Castro JM. Transthoracic echocardiography in women with treated severe pre-eclampsia. *Anaesthesia* 2014 May;69(5):436–444
6. Weisz DE, Shivananda S, Asztalos E, Yee W, Synnes A, Lee SK, et al. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation. *Arch Dis Child Fetal Neonatal Ed* 2015 Jan;100(1):F59–65
7. Horlocker TT. Regional anaesthesia in the patient receiving antithrombotic and antiplatelet therapy. *Br J Anaesth* 2011;107(suppl_1):i96–i106
8. Saving Lives, Improving Mothers' Care – Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009–12. 2014
9. Subbe CP, Kruger M, Rutherford P, Gemmel L. Validation of a modified Early Warning Score in medical admissions. *QJM* 2001 Oct;94(10):521–526
10. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer – 2003–2005. The Seventh Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. 2007
11. Bolte AC, Dekker GA, van Eyck J, van Schijndel RS, van Geijn HP. Lack of agreement between central venous pressure and pulmonary capillary wedge pressure in preeclampsia. *Hypertens Pregnancy* 2000; 19(3):261–271
12. Li YH, Novikova N. Pulmonary artery flow catheters for directing management in pre-eclampsia. *Cochrane Database Syst Rev* 2012 Jun 13;6:CD008882
13. Dennis AT. Management of pre-eclampsia: issues for anaesthetists. *Anaesthesia* 2012 Sep;67(9):1009–1020
14. Dennis AT. Transthoracic echocardiography in obstetric anaesthesia and obstetric critical illness. *Int J Obstet Anesth* 2011 Apr;20(2):160–168
15. Moore TR, Key TC, Reisner LS, Resnik R. Evaluation of the use of continuous lumbar epidural anesthesia for hypertensive pregnant women in labor. *Am J Obstet Gynecol* 1985 Jun 15;152(4):404–412
16. Newsome LR, Bramwell RS, Curling PE. Severe preeclampsia: hemodynamic effects of lumbar epidural anesthesia. *Anesth Analg* 1986 Jan;65(1):31–36
17. Shnider SM, Abboud TK, Artal R, Henriksen EH, Stefani SJ, Levinson G. Maternal catecholamines decrease during labor after lumbar epidural anesthesia. *Am J Obstet Gynecol* 1983 Sep 1;147(1):13–15
18. Reynolds F. Labour analgesia and the baby: good news is no news. *Int J Obstet Anesth* 2011 Jan;20(1):38–50
19. Likis FE, Andrews JC, Collins MR, Lewis RM, Seroogy JJ, Starr SA, et al. Nitrous oxide for the management of labor pain: a systematic review. *Anesth Analg* 2014 Jan;118(1):153–167
20. King TL, Wong CA. Nitrous oxide for labor pain: is it a laughing matter? *Anesth Analg* 2014 Jan;118(1): 12–14
21. Ullman R, Smith LA, Burns E, Mori R, Dowswell T. Parenteral opioids for maternal pain relief in labour. *Cochrane Database Syst Rev* 2010 Sep 8;(9): CD007396. doi(9):CD007396
22. Leong WL, Sng BL, Sia AT. A comparison between remifentanyl and meperidine for labor analgesia: a systematic review. *Anesth Analg* 2011 Oct;113(4): 818–825
23. Schnabel A, Hahn N, Broscheit J, Muellenbach RM, Rieger L, Roewer N, et al. Remifentanyl for labour analgesia: a meta-analysis of randomised controlled trials. *Eur J Anaesthesiol* 2012 Apr;29(4):177–185
24. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. *J Obstet Gynaecol Can* 2014 05;36(5): 416–441
25. Beilin Y, Bodian CA, Haddad EM, Leibowitz AB. Practice patterns of anesthesiologists regarding situations in obstetric anesthesia where clinical management is controversial. *Anesth Analg* 1996 Oct; 83(4):735–741
26. Horlocker TT. What's a nice patient like you doing with a complication like this? Diagnosis, prognosis and prevention of spinal hematoma. *Can J Anaesth* 2004 Jun-Jul;51(6):527–534
27. Ramos-Santos E, Devoe LD, Wakefield ML, Sherline DM, Metheny WP. The effects of epidural anesthesia on the Doppler velocimetry of umbilical and uterine arteries in normal and hypertensive patients during active term labor. *Obstet Gynecol* 1991 Jan;77(1): 20–26
28. Hughes AB, Devoe LD, Wakefield ML, Metheny WP. The effects of epidural anesthesia on the Doppler velocimetry of umbilical and uterine arteries in normal term labor. *Obstet Gynecol* 1990 May;75(5):809–812
29. Jouppila P, Jouppila R, Hollmen A, Koivula A. Lumbar epidural analgesia to improve intervillous blood flow during labor in severe preeclampsia. *Obstet Gynecol* 1982 Feb;59(2):158–161
30. Vricella LK, Louis JM, Mercer BM, Bolden N. Epidural-associated hypotension is more common

- among severely preeclamptic patients in labor. *Am J Obstet Gynecol* 2012 Oct;207(4):335.e1–335.e7
31. Hogg B, Hauth JC, Caritis SN, Sibai BM, Lindheimer M, Van Dorsten JP, et al. Safety of labor epidural anesthesia for women with severe hypertensive disease. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1999 Nov; 181(5 Pt 1):1096–1101
 32. Heesen M, Van de Velde M, Klohr S, Lehberger J, Rossaint R, Straube S. Meta-analysis of the success of block following combined spinal-epidural vs epidural analgesia during labour. *Anaesthesia* 2014 Jan;69(1): 64–71
 33. Abrao KC, Francisco RP, Miyadahira S, Cicarelli DD, Zugaib M. Elevation of uterine basal tone and fetal heart rate abnormalities after labor analgesia: a randomized controlled trial. *Obstet Gynecol* 2009 Jan; 113(1):41–47
 34. Mardirosoff C, Dumont L, Boulvain M, Tramer MR. Fetal bradycardia due to intrathecal opioids for labour analgesia: a systematic review. *BJOG* 2002 Mar;109(3): 274–281
 35. Apfel CC, Saxena A, Cakmakaya OS, Gaiser R, George E, Radke O. Prevention of postdural puncture headache after accidental dural puncture: a quantitative systematic review. *Br J Anaesth* 2010 Sep;105(3): 255–263
 36. Heesen M, Klohr S, Rossaint R, Walters M, Straube S, van de Velde M. Insertion of an intrathecal catheter following accidental dural puncture: a meta-analysis. *Int J Obstet Anesth* 2013 Jan;22(1):26–30
 37. Minty RG, Kelly L, Minty A, Hammett DC. Single-dose intrathecal analgesia to control labour pain: is it a useful alternative to epidural analgesia? *Can Fam Physician* 2007 Mar;53(3):437–442
 38. Viitanen H, Viitanen M, Heikkila M. Single-shot spinal block for labour analgesia in multiparous parturients. *Acta Anaesthesiol Scand* 2005 Aug;49(7): 1023–1029
 39. Sachs A, Smiley R. Post-dural puncture headache: the worst common complication in obstetric anesthesia. *Semin Perinatol* 2014 Oct;38(6):386–394
 40. Beilin Y, Abramovitz S. The anticoagulated parturient. *Int Anesthesiol Clin* 2007 Winter;45(1):71–81
 41. Moodley J, Jjuuko G, Rout C. Epidural compared with general anaesthesia for caesarean delivery in conscious women with eclampsia. *BJOG* 2001 Apr; 108(4):378–382
 42. Wang LP, Paech MJ. Neuroanesthesia for the pregnant woman. *Anesth Analg* 2008 Jul;107(1):193–200
 43. Rocke DA, Scoones GP. Rapidly progressive laryngeal oedema associated with pregnancy-aggravated hypertension. *Anaesthesia* 1992 Feb;47(2):141–143
 44. Tillmann Hein HA. Cardiorespiratory arrest with laryngeal oedema in pregnancy-induced hypertension. *Can Anaesth Soc J* 1984 Mar;31(2):210–212
 45. Quinn AC, Milne D, Columb M, Gorton H, Knight M. Failed tracheal intubation in obstetric anaesthesia: 2 yr national case-control study in the UK. *Br J Anaesth* 2013 Jan;110(1):74–80
 46. Mushambi MC, Kinsella SM, Popat M, Swales H, Ramaswamy KK, Winton AL, et al. Obstetric Anaesthetists' Association and Difficult Airway Society guidelines for the management of difficult and failed tracheal intubation in obstetrics. *Anaesthesia* 2015; 70(11):1286–1306
 47. Obstetric Anaesthetists' Association. OAA DAS obstetric airway guidelines 2015. 2015; Available at: <http://www.oaa-anaes.ac.uk/ui/content/content.aspx?id=3447>. Accessed 12/23, 2015
 48. Difficult Airway Society. Downloads. 2015; Available at: <http://www.das.uk.com/guidelines/downloads.html>. Accessed Dec/23, 2015
 49. King BD, Harris LC, Jr., Greifenstein FE, Elder JDJ, Dripps RD. Reflex circulatory responses to direct laryngoscopy and tracheal intubation performed during general anesthesia. *Anesthesiology* 1951 Sep; 12(5):556–566
 50. Yoo KY, Jeong CW, Park BY, Kim SJ, Jeong ST, Shin MH, et al. Effects of remifentanyl on cardiovascular and bispectral index responses to endotracheal intubation in severe pre-eclamptic patients undergoing Caesarean delivery under general anaesthesia. *Br J Anaesth* 2009 Jun;102(6):812–819
 51. Park BY, Jeong CW, Jang EA, Kim SJ, Jeong ST, Shin MH, et al. Dose-related attenuation of cardiovascular responses to tracheal intubation by intravenous remifentanyl bolus in severe pre-eclamptic patients undergoing Caesarean delivery. *Br J Anaesth* 2011 Jan; 106(1):82–87
 52. Pournajafian A, Rokhtabnak F, Kholdbarin A, Ghodrati M, Ghavam S. Comparison of remifentanyl and fentanyl regarding hemodynamic changes due to endotracheal intubation in preeclamptic parturient candidate for cesarean delivery. *Anesth Pain Med* 2012 Fall;2(2):90–93
 53. Allen RW, James MF, Uys PC. Attenuation of the pressor response to tracheal intubation in hypertensive

- proteinuric pregnant patients by lignocaine, alfentanil and magnesium sulphate. *Br J Anaesth* 1991 Feb;66(2): 216–223
54. Rout CC, Rocke DA. Effects of alfentanil and fentanyl on induction of anaesthesia in patients with severe pregnancy-induced hypertension. *Br J Anaesth* 1990 Oct;65(4):468–474
 55. Yoo KY, Kang DH, Jeong H, Jeong CW, Choi YY, Lee J. A dose-response study of remifentanyl for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia. *Int J Obstet Anesth* 2013 Jan;22(1):10–18
 56. Ashton WB, James MF, Janicki P, Uys PC. Attenuation of the pressor response to tracheal intubation by magnesium sulphate with and without alfentanil in hypertensive proteinuric patients undergoing caesarean section. *Br J Anaesth* 1991 Dec;67(6):741–747
 57. Hood DD, Dewan DM, James FM, 3rd, Floyd HM, Bogard TD. The use of nitroglycerin in preventing the hypertensive response to tracheal intubation in severe preeclampsia. *Anesthesiology* 1985 Sep;63(3): 329–332
 58. Ramanathan J, Sibai BM, Mabie WC, Chauhan D, Ruiz AG. The use of labetalol for attenuation of the hypertensive response to endotracheal intubation in preeclampsia. *Am J Obstet Gynecol* 1988 Sep;159(3): 650–654
 59. Kumar N, Batra YK, Bala I, Gopalan S. Nifedipine attenuates the hypertensive response to tracheal intubation in pregnancy-induced hypertension. *Can J Anaesth* 1993 Apr;40(4):329–333
 60. Pant M, Fong R, Scavone B. Prevention of peri-induction hypertension in preeclamptic patients: a focused review. *Anesth Analg* 2014 Dec;119(6): 1350–1356
 61. Ghoneim MM, Long JP. The interaction between magnesium and other neuromuscular blocking agents. *Anesthesiology* 1970 Jan;32(1):23–27
 62. Dean C, Douglas J. Magnesium and the obstetric anaesthetist. *Int J Obstet Anesth* 2013 Jan;22(1):52–63
 63. Sebbag I, Massey SR, Albert AY, Dube A, Gunka V, Douglas MJ. A Prospective Observational Comparison Between Arm and Wrist Blood Pressure During Scheduled Cesarean Delivery. *Anesth Analg* 2015 Sep;121(3):767–775
 64. Langesaeter E. Is it more informative to focus on cardiac output than blood pressure during spinal anesthesia for cesarean delivery in women with severe preeclampsia? *Anesthesiology* 2008 May;108(5): 771–772
 65. Dyer RA, Piercy JL, Reed AR, Lombard CJ, Schoeman LK, James MF. Hemodynamic changes associated with spinal anesthesia for cesarean delivery in severe preeclampsia. *Anesthesiology* 2008 May; 108(5):802–811
 66. Cooper DW. Caesarean delivery vasopressor management. *Curr Opin Anaesthesiol* 2012 Jun;25(3): 300–308
 67. Morgan PJ. The Effect of Increasing Central Blood Volume to Decrease the Incidence of Hypotension Following Spinal Anesthesia for Cesarean Section. Blackwell Publishing Ltd; 2007:89–100
 68. Henke VG, Bateman BT, Leffert LR. Focused review: spinal anesthesia in severe preeclampsia. *Anesth Analg* 2013 Sep;117(3):686–693
 69. Banerjee A, Stocche RM, Angle P, Halpern SH. Preload or coload for spinal anesthesia for elective Cesarean delivery: a meta-analysis. *Can J Anaesth* 2010 Jan;57(1):24–31
 70. Kee W. Prevention of maternal hypotension after regional anaesthesia for caesarean section. *Current Opinion In Anesthesiology* 2010;23(3):304–309
 71. Dyer R, Farina Z, Joubert I, Du Toit P, Meyer M, Torr G, et al. Crystalloid preload versus rapid crystalloid administration after induction of spinal anaesthesia (coload) for elective Caesarean section. *Anaesth Intensive Care* 2004;32(3):351–357
 72. Heesen M, Stewart A, Fernando R. Vasopressors for the treatment of maternal hypotension following spinal anaesthesia for elective caesarean section: past, present and future. *Anaesthesia* 2015 Mar;70(3): 252–257
 73. Aya AG, Mangin R, Vialles N, Ferrer JM, Robert C, Ripart J, et al. Patients with severe preeclampsia experience less hypotension during spinal anesthesia for elective cesarean delivery than healthy parturients: a prospective cohort comparison. *Anesth Analg* 2003 Sep;97(3):867–872
 74. Clark VA, Sharwood-Smith GH, Stewart AV. Ephedrine requirements are reduced during spinal anaesthesia for caesarean section in preeclampsia. *Int J Obstet Anesth* 2005 Jan;14(1):9–13
 75. Tihtonen K, Koobi T, Yli-Hankala A, Huhtala H, Uotila J. Maternal haemodynamics in pre-eclampsia compared with normal pregnancy during caesarean delivery. *BJOG* 2006 Jun;113(6):657–663

76. Visalyaputra S, Rodanant O, Somboonviboon W, Tantivitayatan K, Thienthong S, Saengchote W. Spinal versus epidural anesthesia for cesarean delivery in severe preeclampsia: a prospective randomized, multicenter study. *Anesth Analg* 2005 Sep;101(3): 862–8
77. Sharwood-Smith G, Clark V, Watson E. Regional anaesthesia for caesarean section in severe preeclampsia: spinal anaesthesia is the preferred choice. *Int J Obstet Anesth* 1999 Apr;8(2):85–89
78. Hood DD, Curry R. Spinal versus epidural anesthesia for cesarean section in severely preeclamptic patients: a retrospective survey. *Anesthesiology* 1999 May;90(5): 1276–1282
79. Chiu CL, Mansor M, Ng KP, Chan YK. Retrospective review of spinal versus epidural anaesthesia for caesarean section in preeclamptic patients. *Int J Obstet Anesth* 2003 Jan;12(1):23–27
80. Wallace DH, Leveno KJ, Cunningham FG, Giesecke AH, Shearer VE, Sidawi JE. Randomized comparison of general and regional anesthesia for cesarean delivery in pregnancies complicated by severe preeclampsia. *Obstet Gynecol* 1995 Aug;86(2):193–199
81. Dyer RA, Els I, Farbas J, Torr GJ, Schoeman LK, James MF. Prospective, randomized trial comparing general with spinal anesthesia for cesarean delivery in preeclamptic patients with a nonreassuring fetal heart trace. *Anesthesiology* 2003 discussion 5A–6A; Sep; 99(3):561–569
82. Riley ET, Cohen SE, Macario A, Desai JB, Ratner EF. Spinal versus epidural anesthesia for cesarean section: a comparison of time efficiency, costs, charges, and complications. *Anesth Analg* 1995 Apr;80(4): 709–712
83. Aya AG, Vialles N, Tanoubi I, Mangin R, Ferrer JM, Robert C, et al. Spinal anesthesia-induced hypotension: a risk comparison between patients with severe preeclampsia and healthy women undergoing preterm cesarean delivery. *Anesth Analg* 2005 Sep;101(3): 869–75
84. Ramanathan J, Vaddadi AK, Arheart KL. Combined spinal and epidural anesthesia with low doses of intrathecal bupivacaine in women with severe preeclampsia: a preliminary report. *Reg Anesth Pain Med* 2001 Jan-Feb;26(1):46–51
85. Berends N, Teunkens A, Vandermeersch E, Van de Velde M. A randomized trial comparing low-dose combined spinal-epidural anesthesia and conventional epidural anesthesia for cesarean section in severe preeclampsia. *Acta Anaesthesiol Belg* 2005;56(2): 155–162
86. Tyagi A, Kakkar A, Kumar S, Sethi AK, Sallhotra R. ED50 of hyperbaric bupivacaine with fentanyl for cesarean delivery under combined spinal epidural in normotensive and preeclamptic patients. *Reg Anesth Pain Med* 2012 Jan-Feb;37(1):40–44
87. Mellor DJ, Bodenham A. Infiltration anaesthesia in the management of Caesarean section in a patient with peripartum cardiomyopathy. *Anaesthesia* 1996;51(4): 409–409
88. Moir DD. Local anaesthetic techniques in obstetrics. *Br J Anaesth* 1986;58(7):747–759
89. Langesaeter E, Rosseland LA, Stubhaug A. Haemodynamic effects of oxytocin in women with severe preeclampsia. *Int J Obstet Anesth* 2011 Jan; 20(1):26–29
90. Mhyre JM, Riesner MN, Polley LS, Naughton NN. A series of anesthesia-related maternal deaths in Michigan, 1985–2003. *Anesthesiology* 2007 Jun; 106(6):1096–1104
91. Robins K, Lyons G. Intraoperative awareness during general anesthesia for cesarean delivery. *Anesth Analg* 2009 Sep;109(3):886–890
92. Pandit JJ, Andrade J, Bogod DG, Hitchman JM, Jonker WR, Lucas N, et al. The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: summary of main findings and risk factors. *Anaesthesia* 2014 Oct;69(10):1089–1101
93. Sebel PS, Bowdle TA, Ghoneim MM, Rampil JJ, Padilla RE, Gan TJ, et al. The incidence of awareness during anesthesia: a multicenter United States study. *Anesth Analg* 2004 Sep;99(3):833–9
94. Cook TM, Andrade J, Bogod DG, Hitchman JM, Jonker WR, Lucas N, et al. The 5th National Audit Project (NAP5) on accidental awareness during general anaesthesia: patient experiences, human factors, sedation, consent and medicolegal issues. *Anaesthesia* 2014 Oct;69(10):1102–1116
95. Choi PT, Galinski SE, Takeuchi L, Lucas S, Tamayo C, Jadad AR. PDPH is a common complication of neuraxial blockade in parturients: a meta-analysis of obstetrical studies. *Can J Anaesth* 2003 May;50(5): 460–469
96. Gleeson CM, Reynolds F. Accidental dural puncture rates in UK obstetric practice. *Int J Obstet Anesth* 1998 Oct;7(4):242–246
97. Ruppen W, Derry S, McQuay H, Moore RA. Incidence of epidural hematoma, infection, and neurologic injury in obstetric patients with epidural analgesia/anesthesia. *Anesthesiology* 2006 Aug;105(2): 394–399

THE FIGO TEXTBOOK OF PREGNANCY HYPERTENSION

98. Reynolds F. Damage to the conus medullaris following spinal anaesthesia. *Anaesthesia* 2001 Mar;56(3): 238–247
99. Moen V, Dahlgren N, Irestedt L. Severe neurological complications after central neuraxial blockades in Sweden 1990–1999. *Anesthesiology* 2004 Oct;101(4): 950–959
100. The Royal College of Anaesthetists. National Audit of Major Complications of Central Neuraxial Block in the United Kingdom. 2009; Available at: <http://www.rcoa.ac.uk/nap3>. Accessed Apr/13, 2015
101. World Health Organization (WHO). WHO's pain ladder. 2012; Available at: <http://www.who.int/cancer/palliative/painladder/en/>. Accessed 07/19, 2015
102. Makris A, Thornton C, Hennessy A. Postpartum hypertension and nonsteroidal analgesia. *Am J Obstet Gynecol* 2004 Feb;190(2):577–578
103. Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. *Pediatrics* 2013 Sep;132(3): e796–809
104. Lazaryan M, Shasha-Zigelman C, Dagan Z, Berkovitch M. Codeine should not be prescribed for breastfeeding mothers or children under the age of 12. *Acta Paediatr* 2015 Jun;104(6):550–556
105. Haliloglu M, Ozdemir M, Uzturk N, Cenksoy PO, Bakan N. Perioperative low-dose ketamine improves postoperative analgesia following Cesarean delivery with general anesthesia. *J Matern Fetal Neonatal Med* 2015 Apr 7:1–5
106. Seyhan TO, Tugrul M, Sungur MO, Kayacan S, Telci L, Pembeci K, et al. Effects of three different dose regimens of magnesium on propofol requirements, haemodynamic variables and postoperative pain relief in gynaecological surgery. *Br J Anaesth* 2006 Feb; 96(2):247–252
107. Fuller JG, McMorland GH, Douglas MJ, Palmer L. Epidural morphine for analgesia after caesarean section: a report of 4880 patients. *Can J Anaesth* 1990 Sep; 37(6):636–640
108. Albrecht E, Kirkham KR, Liu SS, Brull R. The analgesic efficacy and safety of neuraxial magnesium sulphate: a quantitative review. *Anaesthesia* 2013 Feb; 68(2):190–202
109. van Tuijl I, van Klei WA, van der Werff DB, Kalkman CJ. The effect of addition of intrathecal clonidine to hyperbaric bupivacaine on postoperative pain and morphine requirements after Caesarean section: a randomized controlled trial. *Br J Anaesth* 2006 Sep; 97(3):365–370
110. Bamigboye AA, Hofmeyr GJ. Local anaesthetic wound infiltration and abdominal nerves block during caesarean section for postoperative pain relief. *Cochrane Database Syst Rev* 2009 Jul 8;(3):CD006954. doi(3):CD006954
111. Simavli S, Kaygusuz I, Kinay T, Akinci Baylan A, Kafali H. Bupivacaine-soaked absorbable gelatin sponges in caesarean section wounds: effect on postoperative pain, analgesic requirement and haemodynamic profile. *Int J Obstet Anesth* 2014 Nov; 23(4):302–308
112. Kainu JP, Sarvela J, Halonen P, Puro H, Toivonen HJ, Halmesmaki E, et al. Continuous wound infusion with ropivacaine fails to provide adequate analgesia after caesarean section. *Int J Obstet Anesth* 2012 Apr; 21(2):119–124
113. Bamigboye AA, Hofmeyr GJ. Caesarean section wound infiltration with local anaesthesia for postoperative pain relief - any benefit? *S Afr Med J* 2010 May 4;100(5):313–319
114. Zohar E, Shapiro A, Eidinov A, Fishman A, Fredman B. Postcesarean analgesia: the efficacy of bupivacaine wound instillation with and without supplemental diclofenac. *J Clin Anesth* 2006 Sep;18(6):415–421
115. Rackelboom T, Le Strat S, Silvera S, Schmitz T, Bassot A, Goffinet F, et al. Improving continuous wound infusion effectiveness for postoperative analgesia after cesarean delivery: a randomized controlled trial. *Obstet Gynecol* 2010 Oct;116(4): 893–900
116. Mishriky BM, George RB, Habib AS. Transversus abdominis plane block for analgesia after Cesarean delivery: a systematic review and meta-analysis. *Can J Anaesth* 2012 Aug;59(8):766–778
117. Telnes A, Skogvoll E, Lonnée H. Transversus abdominis plane block vs. wound infiltration in Caesarean section: a randomised controlled trial. *Acta Anaesthesiol Scand* 2015;59(4):496–504
118. Wolfson A, Lee AJ, Wong RP, Arheart KL, Penning DH. Bilateral multi-injection iliohypogastric-ilioinguinal nerve block in conjunction with neuraxial morphine is superior to neuraxial morphine alone for postcesarean analgesia. *J Clin Anesth* 2012 Jun;24(4): 298–303
119. Bell EA, Jones BP, Olufolabi AJ, Dexter F, Phillips-Bute B, Greengrass RA, et al. Iliohypogastric-ilioinguinal peripheral nerve block for post-Cesarean delivery analgesia decreases morphine

- use but not opioid-related side effects. *Can J Anaesth* 2002 Aug-Sep;49(7):694–700
120. Hussein J, Goodburn EA, Damisoni H, Lema V, Graham W. Monitoring obstetric services: putting the ‘UN Guidelines’ into practice in Malawi: 3 years on. *Int J Gynaecol Obstet* 2001 Oct;75(1):63–73; discussion 74
121. Fenton PM, Whitty CJ, Reynolds F. Caesarean section in Malawi: prospective study of early maternal and perinatal mortality. *BMJ* 2003 Sep 13;327(7415):587
122. Olufolabi AJ, Atito-Narh E, Eshun M, Ross VH, Muir HA, Owen MD. Teaching neuraxial anesthesia techniques for obstetric care in a Ghanaian referral hospital: achievements and obstacles. *Anesth Analg* 2015 Jun;120(6):1317–1322
123. Okafor UV, Aniebue U. Anaesthesia for uterine rupture in a Nigerian teaching hospital: maternal and fetal outcome. *Int J Obstet Anesth* 2006 Apr;15(2): 124–128
124. Ismail S, Siddiqui S, Shafiq F, Ishaq M, Khan S. Blood transfusion in patients having caesarean section: a prospective multicentre observational study of practice in three Pakistan hospitals. *Int J Obstet Anesth* 2014 Aug;23(3):253–259
125. Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. *Pregnancy Hypertens* 2014 2015/01;4(2):105–145
126. National Collaborating Centre for Women’s and Children’s Health (UK). CG107: Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. NICE: Guidance 2010 Aug; 2010 Aug
127. Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. *PLoS One* 2014;9(12):e113715
128. Lowe SA, Bowyer L, Lust K, McMahon LP, Morton MR, North RA, et al. The SOMANZ guideline for the management of hypertensive disorders of pregnancy 2014. *Aust N Z J Obstet Gynaecol* 2015; 55(1):11–6

